Ascelia Pharma AB (publ) (Nasdaq Stockholm: ACE) develops and commercializes novel drugs for orphan oncology indications, focusing on unmet needs in rare cancer conditions. The company offers Orviglance, a novel oral manganese-based contrast agent for magnetic resonance imaging to detect and visualize focal liver lesions including metastases and primary tumors in patients with impaired kidney function who cannot use gadolinium-based agents; and Oncoral, an oral irinotecan chemotherapy tablet designed for improved safety and patient outcomes in gastric cancer and other difficult-to-treat cancers, with potential orphan drug status in the US and Europe. Ascelia Pharma operates globally with emphasis on the US and European markets, maintains headquarters in Malmö, Sweden, and traces origins to 1999. Recent developments include positive Phase 3 SPARKLE trial results for Orviglance in 2024 confirming superior visualization of liver lesions versus unenhanced MRI, with FDA orphan drug designation and favorable meeting outcomes confirming plans for a New Drug Application submission in mid-2025; a fully subscribed SEK 105 million rights issue in Q3 2024 extending cash runway to late 2025; gross proceeds of SEK 43 million from warrant exercises in April 2025; and a directed share issue raising approximately SEK 30 million in September 2025. The company also reports preparation for Phase 2 trials of Oncoral following successful Phase 1 completion and acceptance of SPARKLE data abstracts at the 2025 European Society of Gastrointestinal and Abdominal Radiology meeting.